CD19 and diffuse large B-cell lymphoma: In this study, we analyzed FDG‐PET‐based radiomic phenotypes in R/R DLBCL patients treated with CD19‐targeted CAR T‐cell therapy, aiming to identify those patients who would benefit most from treatment.